Moderators: cash4
Search This Board: 
Created: 08/06/2022 06:36:58 PM - Followers: 0 - Board type: Free - Posts Today: 0

QNCX

Quince Therapeutics, Inc.



http://www.quincetx.com/

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, provided an overview of its strategic growth plan in conjunction with its corporate name change today. The launch of Quince Therapeutics marks a strategic shift in focus as the company prioritizes the clinical development of its highly differentiated bone-targeting drug platform and lead precision bone growth molecule, NOV004, to address major, unmet medical needs across multiple skeletal therapeutic indications. Quince also announced that the company plans to pursue the strategic expansion of its development pipeline through opportunistic in-licensing and acquisition of clinical-stage assets targeting debilitating and rare diseases, in addition to disclosing the company’s intent to out-license its legacy neuroscience and antiviral assets.
 



Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. Our lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site. Preclinical studies demonstrate that this results in rapid increases in bone density, strength, and other severe bone diseases. Quince’s lead compound NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. Our pipeline also includes legacy neuroscience and antiviral programs available for out-licensing.

Initiates Nasdaq Trading Under New Ticker Symbol “QNCX”

Quince’s ticker symbol on the Nasdaq Stock Market will begin to trade under “QNCX” effective at the open of market trading today, Monday, August 1, 2022. The corporate name change to Quince Therapeutics, Inc. does not affect the rights of the company’s stockholders with respect to the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.
 

Quince discovered a bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone diseases to promote more rapid healing with fewer off-target safety concerns. Our proprietary science enables the connection of bone-specific targeting molecules to approved drugs, biologics, or radionuclides via small biological linker molecules. The result is the delivery of the proven therapeutic payload directly to the site of disease or injury. Quince’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site. Preclinical studies demonstrate that this results in rapid increases in bone density, strength and healing directly at the site of injury.


About Quince Therapeutics

Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.
 

Founded: June 20, 2012
CEO: Dirk Thye
Chief medical officer: Dr. Karen Smith cortexyme.com
 

Leadership

 
 
Black and white picture of Dirk Thye

Dirk Thye, M.D.

Chief Executive Officer
Black and white picture of Karen Smith

Karen Smith, M.D, Ph.D.

Chief Medical Officer
Black and white picture of Brendan Hannah

Brendan Hannah

Chief Business Officer
Ted Monohon

Ted Monohon

Chief Accounting Officer and Principal Financial Officer
Stewart Lowe

Stewart Low

Head of Discovery
Maureen Roden

Maureen Roden

Vice President, Clinical Development
Mary Ellen Sillivos

Mary Ellen Sillivos

Vice President, Human Resources
Stacy Roughan

Stacy Roughan

Vice President, Corporate Communications & Investor Relations
 

Board of Directors

 
 

David Lamond

President, En Pointe, LLC

Dirk Thye, M.D.

Chief Executive Officer, Quince Therapeutics

June Bray

Previously SVP, Global Regulatory Affairs and Medical Writing, Allergan

Philip Low, Ph.D.

Professor of Chemistry, Purdue University
 

Margaret McLoughlin, Ph.D.

Previously Executive Director Worldwide Business Development, Pfizer

Una Ryan, OBE, Ph.D.

Previously Chief Executive Officer, AVANT Immunotherapeutics

Marwan Sabbagh, M.D., FAAN

Professor of Neurology, Alzheimer’s and Memory Disorders Division, Barrow Neurological Institute

Christopher Senner

Chief Financial Officer, Exelixis

NEWS

Stock Quote




Contacts

https://twitter.com/Quince_Tx

https://www.linkedin.com/company/quincetx-inc

Quince Therapeutics Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

QUINCE THERAPEUTICS, INC.

601 Gateway Blvd Ste 1250

South San Francisco, CA 94080

(415) 910-5717
 


QNCX SECURITY DETAILS

Share Structure

 
Market Cap Market Cap
62,110,720
08/05/2022
Authorized Shares
Not Available
 
Outstanding Shares
30,150,835
05/03/2022
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#1
https://www.otcmarkets.com/filing/html?id=15980132&guid=AKk-kW7ZRh7-B3h cash4 08/06/2022 06:38:02 PM
Post Subject